Previous 10 | Next 10 |
Lipocine (NASDAQ: LPCN ): Q1 GAAP EPS of -$0.14 in-line. More news on: Lipocine Inc., Earnings news and commentary, , Read more ...
SALT LAKE CITY , May 8, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019 , and provided a corporate update. First Quarter and Recent Corporate Highlights Anno...
During the 1992 presidential campaign, candidate Bill Clinton used the slogan “It’s the economy stupid” in the race with opponent George H.W. Bush. Due to a short recession during the time frame, the slogan proved to be prophetic to the final outcome of the election, with ...
SALT LAKE CITY , April 3, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc. ("Clarus") in the United States District ...
Checking off one of the boxes cited in the CRL it received in May 2018, Lipocine (NASDAQ: LPCN ) announces topline results from a study evaluating TLANDO's effects on blood pressure. More news on: Lipocine Inc., Healthcare stocks news, Stocks on the move, Read more ...
SALT LAKE CITY , March 27, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory Blood Pressure Monitoring clinical study (NCT03868059) ("ABPM Study") ...
SALT LAKE CITY , March 26, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 clinical results as part of The International Liver Congress™ 2019, the a...
The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne...
SALT LAKE CITY , March 21, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate overview and LPCN 1144's therapeutic potential for non-alcoholic ste...
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...